Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 4/20 | 0.32 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.30 |
| ▸ | NPY1R | P25929 | 2/20 | 0.30 |
| ▸ | NPY2R | P49146 | 2/20 | 0.30 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16446673 | 1.00 | NPY4R (0.32) | NPY4RC3AR1ITGB3ITGA2BALOX15 | |
| SCHEMBL2367598 | 0.96 | C3AR1 (0.37) | NPY4RC3AR1ITGB3ITGA2B | |
| SCHEMBL6756631 | 0.96 | C3AR1 (0.37) | NPY4RC3AR1ITGB3ITGA2B | |
| SCHEMBL30989231 | 0.89 | FOLH1 (0.35) | NPY4RC3AR1ITGB3ITGA2BALOX15 | |
| SCHEMBL23690778 | 0.80 | MEN1 (0.40) | NPY4RC3AR1ITGB3ITGA2BALOX15 | |
| SCHEMBL20221707 | 0.80 | MEN1 (0.40) | NPY4RC3AR1ITGB3ITGA2BALOX15 | |
| SCHEMBL27855641 | 0.78 | ALOX15 (0.35) | ALOX15MEN1KMT2ACYP1A2SMN1; SMN2 | |
| SCHEMBL29836396 | 0.77 | ALOX15 (0.39) | NPY4RC3AR1ITGB3ITGA2BALOX15 | |
| SCHEMBL30068909 | 0.77 | ALOX15 (0.39) | NPY4RC3AR1ITGB3ITGA2BALOX15 | |
| SCHEMBL28827545 | 0.76 | ALOX15 (0.36) | ALOX15MEN1KMT2ACYP1A2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170119864-A1 | SACCHARIDE VACCINE FORMULATION | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2017-05-04 | — | — | US | disclosed |
| EP-3030258-A1 | SACCHARIDE VACCINE FORMULATION | GlaxoSmithKline Biologicals S.A. (BE) | 2016-06-15 | — | — | EP | disclosed |
| WO-2015018753-A1 | SACCHARIDE VACCINE FORMULATION | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2015-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170119864-A1 | SACCHARIDE VACCINE FORMULATION | STT3B, STT3A, DDOST | NPY4R 3242/4885C3AR1 2674/4885ITGB3 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.